WORLD-ANTI-SMOKING-PLCY
3.4.2024 07:01:29 CEST | Business Wire | Press release
We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index (https://antismoking.global/). The index assesses around 5.5 billion people, nearly 70 percent of the world's population. It offers an analysis of the public policies to eradicate smoking in 69 countries across four regions. The Index delves into the intricacies of alternative nicotine products, scrutinizing aspects such as regulatory frameworks, prohibitions, taxation, and governmental measures for switching from smoking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402477735/en/
The top 20 countries in the global anti-smoking index, led by the United Kingdom, Sweden, and Slovakia in the podium positions, collectively impact almost 1 billion people worldwide. European nations dominate the list, with 15 out of the 20 spots occupied by countries from this region. However, non-European nations like the United States, Lebanon, New Zealand, Canada, and Saudi Arabia also make significant strides in terms of regulations.
The index emphasizes the urgent need for global advancements in anti-smoking policies. Finding a balance between traditional measures and innovative approaches, including alternative nicotine products, is key to success. The Index calls for a holistic approach encompassing alternative products to address the gaps in regulation.
Global policies differ radically in receptiveness, with vaping facing sales bans despite growing evidence on its harm reduction. Thus, seventeen countries have prohibited vaping. Tobacco Heated Products (THP) policies show similar regional bifurcation patterns. Thirteen countries prohibit THP, mostly in South America and Asia. Snus faces widespread prohibitions in the European Union, except in Sweden. China with bans on THP and nicotine pouches and heavy restriction of vaping and snus scored 51st place. India scored last globally for completely prohibiting all nicotine alternatives. In addition to forgoing harm reduction benefits, the blanket ban fuels illicit trade.
In the Americas, Canada and the United States are open to vaping and other alternatives, while many Latin American countries ban them. New Zealand leads in vaping in the Asia Pacific, while Australia, India, Japan, Thailand, and Vietnam have banned it. Japan, however, is the frontrunner for THP and snus.
In the MENA region, only Lebanon and Saudi Arabia have progressive harm reduction stances, while other countries prohibit alternatives. Nicotine pouches have avoided significant regulatory scrutiny, but their potential depends on recognition for health merits outside of the EU and US.
“With over 8 million lives lost annually to smoking-related diseases, the need for effective anti-smoking measures is more urgent than ever. Nations like Sweden and New Zealand are leading the way by embracing innovative nicotine products in the fight against smoking. Their public policies allowing alternatives have yielded remarkable results, with smoking rates around 5 percent - nearly smoke-free. This success highlights the vital role innovation must play in consigning smoking to history. Policymakers worldwide must follow the example set by these countries, fully harnessing safer products to uproot smoking's toll on global health,” stated Federico N. Fernandez, the CEO of We Are Innovation.
ABOUT WE ARE INNOVATION
We Are Innovation is a dynamic network of individuals and institutions who fervently believe in the power of innovation to drive progress and solve the world’s most pressing problems. With a global presence encompassing over 40 think tanks, foundations, and NGOs, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are spearheading transformative change on a global scale. To learn more visit us at https://weareinnovation.global/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402477735/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
